4th Annual COMPANION DIAGNOSTICS FORUM
Precision Medicine without Borders
Precision Medicine without Borders
October 29-30, 2019
New Jersey Hospital Association Conference and Event Center
Princeton, NJ
Join us at the 4th Annual Companion Diagnostics Conference in Princeton. Precision Medicine has surpassed its original vision directed to genomics and cancer and now encompasses a host of diagnostic and therapeutic modalities. In the time since the formal announcement in 2015, drugs and assays have been developed based on a broader array of pathways and targets. Precision Medicine has also expanded beyond the geographic borders of the original targeted market regions to new countries, each with its own market needs and regulations.
Jeff Evelhoch
Vice President, Head of Translational Biomarkers
Merck & Co.
Steve Anderson
Senior Vice President
LabCorp
What has driven this expansion? What challenges are presented? At this Forum, we explore how Precision Medicine has been taken up across geographic borders, expanded to include new therapeutic areas, and broadened to develop novel drugs and assay types. Of particular interest for the Forum are the challenges of bringing precision medicine to international markets – for example, how lessons learned within country can be applied (or not!) to other countries.
Talk Recordings from the previous Companion Diagnostics Forums are available to view, you will just need to fill in a simple form to view. Call for Abstracts is now Open.
Compelling reasons to attend this year’s Forum:
- Wide range of high quality attendees and speakers from key Pharmas and Biotechs, Life Science Suppliers and more
- Comfortable size (capped at 225 Attendees) and configuration designed to encourage networking
- Free full video recordings from previous events – get an idea of the event, topics covered, speaker styles.
- Attendee Pricing 75% less below other CDx and Biomarker events. Special discounted pricing to Pharmas and Biotechs to encourage broad participation of key R&D attendees in discussions
- Located near research and development facilities of key Companion Diagnostic Pharmas to encourage their broad participation and ability to meet T&L restrictions. Cross-promotion at internal Company events that PlanetConnect manages.
- New topics on the promotion and uptake of Precision Dx and Rx
- Special Panels including:
- Clinical and Regulatory Experts in Precision Medicine including “Ask me Anything! (on Precision Medicine)” session
- Diagnostics Accuracy and Innovation Act – Implementation and Impact
Targeted audience: Those Developing and Launching Precision Diagnostics and Therapeutics in global and domestic markets
- Vice Presidents, Executive/Senior Directors, Senior Scientists in related fields including Licensing and Regulatory
- Laboratory and Technology Directors
- Project Managers to manage international collaborations (technical, logistical, and transitioning projects to partners)
- Technology leaders and researchers – precision tools, processes, platforms, informatics
- Researchers in precision assays, diagnostics (basic, development, validation, execution)
- Researchers in novel precision therapeutics – vaccines, biologics, and small molecules
View the detailed list of previous Attendees Companies and Job Titles
CALL FOR ABSTRACTS
Developing and Launching Precision Diagnostics and Therapeutics
CDx Forum and the Precision Medicine Leadership Summit
A joint forum dedicated to the international promotion of Precision Medicine
Intra- and inter-country Variations:
- Market Access Decision-making Frameworks, Processes, Strategies
- Evidence Generation and Requirements For Medicines And Diagnostics
- Categorization Of Payers Based On Decision-making Frameworks
- National vs Local Coverage Determination
- Reimbursement and Funding of diagnostics
- Viable business models for Pharma, Diagnostics, and CRO partners
Domestic and International Collaboration Opportunities:
- Different Stakeholder Involvement in Development, Filing, and Approval
- Coordination among R&D, regulatory, market access and reimbursement processes and for the duration of the product life-cycle
- Evidence Timelines To Achieve Diagnostics Market Access Approval Of Companion Or Complementary Diagnostics
- Managing the timing for optimal roll-out among diagnostics and pharmaceutical manufacturers, regulators, payers, and stakeholders
- Lessons learned from early engagement among diagnostics companies, pharmaceutical manufacturers and payers to ensure diagnostics are reimbursed at the time of launch
- Educating physicians on companion diagnostics and precision medicine
Special Topics:
- Lessons learned from Patient Experiences with Precision Medicine – (Dx and Rx)
- Education and uptake of precision medicine (Dx and Rx)
- Precision Medicine (Dx and Rx) for rare diseases
- Choosing between IVDs and LDTs for international markets
- Biomarkers in drug discovery and development
- Emerging technology options
- Novel biomarkers in drug development and transition to the clinic
- Digital Technologies – e.g., NGS, pathology image analysis
- Analytics and Informatics
- Clinical Informatics – the totality of data gathered on a patient before, during, and after a trial
- Connectivity enabled by personal contacts and technology platforms
- Precision medicine in the cloud